Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

N/A

1(14.3%)

7Total

Phase 3(4)

Phase 1(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02395016Phase 3Completed

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Role: collaborator

NCT02329860Phase 3Completed

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Role: collaborator

NCT03607357Not ApplicableCompleted

High Flow Nasal Oxygen and Acute Left Heart Failure

Role: collaborator

NCT03884751Phase 1Completed

Chimeric Antigen Receptor T Cells Targeting Glypican-3

Role: collaborator

NCT03236636Phase 3Unknown

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Role: collaborator

NCT01972672Phase 2Completed

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Role: collaborator

NCT03631459Unknown

A Multicenter Real World Study of Kanglaite for Cancer Cachexia

Role: collaborator

NCT01404260Phase 3Completed

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer

Role: collaborator

All 8 trials loaded